308 related articles for article (PubMed ID: 23373781)
1. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?
Otrock ZK; Tiu RV; Maciejewski JP; Sekeres MA
Expert Rev Hematol; 2013 Feb; 6(1):59-68. PubMed ID: 23373781
[TBL] [Abstract][Full Text] [Related]
2. [Progress of cytogenetic detection in myelodysplastic syndromes].
Zhou QB; Hu XM; Liu -; Ma R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1536-40. PubMed ID: 22169320
[TBL] [Abstract][Full Text] [Related]
3. Updates in cytogenetics and molecular markers in MDS.
Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
[TBL] [Abstract][Full Text] [Related]
4. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
Kokate P; Dalvi R; Koppaka N; Mandava S
Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
[TBL] [Abstract][Full Text] [Related]
5. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
7. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
8. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.
Evans AG; Ahmad A; Burack WR; Iqbal MA
Mod Pathol; 2016 Oct; 29(10):1183-99. PubMed ID: 27389314
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
Mecucci C
Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
[TBL] [Abstract][Full Text] [Related]
10. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases: challenges and difficulties in a large and emerging country.
Velloso ED; Chauffaille ML; Peliçario LM; Tanizawa RS; Toledo SR; Gaiolla RD; Lopes LF
Braz J Med Biol Res; 2013 Jan; 46(1):85-90. PubMed ID: 23314345
[TBL] [Abstract][Full Text] [Related]
12. Diabetes Insipidus as an Initial Presentation of Myelodysplastic Syndrome: Diagnosis with Single-Nucleotide Polymorphism Array-Based Karyotyping.
Sun R; Wang C; Zhong X; Wu Y
Tohoku J Exp Med; 2016 Apr; 238(4):305-10. PubMed ID: 27075406
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.
Steensma DP; List AF
Mayo Clin Proc; 2005 May; 80(5):681-98. PubMed ID: 15887439
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
[TBL] [Abstract][Full Text] [Related]
15. The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes.
Nybakken GE; Bagg A
J Mol Diagn; 2014 Mar; 16(2):145-58. PubMed ID: 24457119
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
17. The use of cytogenetic microarrays in myelodysplastic syndrome characterization.
Shaffer LG; Ballif BC; Schultz RA
Methods Mol Biol; 2013; 973():69-85. PubMed ID: 23412784
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic methods in the diagnosis of myelodysplastic syndromes. A review.
Lukackova R; Gerykova Bujalkova M; Majerova L; Mladosievicova B
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):339-45. PubMed ID: 24263214
[TBL] [Abstract][Full Text] [Related]
20. [New advance of research on prognostic factors in myelodysplastic syndrome--review].
Wei J; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1465-72. PubMed ID: 19099666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
